Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines made from recombinant yeast cells.

M R Hilleman, R Ellis

    Vaccine
    |June 1, 1986
    PubMed
    Summary

    Recombinant DNA technology enables the production of safe and effective vaccines, such as the hepatitis B vaccine. This approach overcomes limitations associated with traditional plasma-derived vaccines.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The enhancement and properties of the complement-fixing antigens of lymphogranuloma venereum.

    Federation proceedings·2010
    Same author

    Studies on lymphogranuloma venereum complement-fixing antigens the solubility in ether of an active fraction.

    Journal of immunology (Baltimore, Md. : 1950)·2010
    Same author

    Studies on lymphogranuloma venereum complement-fixing antigens; enhancement by phenol or boiling.

    Journal of immunology (Baltimore, Md. : 1950)·2010
    Same author

    Studies on lymphogranuloma venereum complement-fixing antigens; fractionation with organic solvents of antigens of the psittacosis lymphogranuloma venereum group.

    Journal of bacteriology·2010
    Same author

    On use of urea- and phenol-treated skin test antigens for diagnosis of lymphogranuloma venereum.

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
    Same author

    Double-stranded polynucleotides as interferon inducers.

    The Journal of general physiology·2009

    Area of Science:

    • Biotechnology
    • Vaccinology
    • Molecular Biology

    Background:

    • Traditional vaccines rely on antigens purified from human sources, posing supply and safety challenges.
    • Plasma-derived vaccines, like the current hepatitis B vaccine, require extensive purification and safety measures.
    • Limitations include the availability of carrier plasma and the need to inactivate infectious agents.

    Purpose of the Study:

    • To highlight the role of recombinant DNA technology in vaccine development.
    • To present recombinant protein antigens as a safer and more feasible alternative.
    • To discuss the advantages over traditional plasma-derived vaccine production methods.

    Main Methods:

    • Utilizing prokaryotic and eukaryotic cells for recombinant polypeptide and protein antigen production.
    • Applying recombinant DNA technology for antigen synthesis.
    • Culturing genetically modified cells for large-scale antigen expression.

    Main Results:

    • Recombinant DNA technology facilitates the production of safe, efficacious, and economically feasible vaccines.
    • This method offers a viable alternative to plasma-derived vaccine production.
    • Overcomes limitations related to plasma supply and purification complexities.

    Conclusions:

    • Recombinant DNA technology is revolutionizing vaccine manufacturing.
    • It provides a scalable and reliable method for producing critical vaccine components.
    • Enables the development of next-generation vaccines with improved safety and accessibility.

    Related Experiment Videos